RO7105705 is an
anti-tau antibody that targets a protein involved in the progression of
Alzheimer's disease.
Participants will be randomly assigned to either
the study treatment or placebo. Researchers will measure changes in
severity of dementia symptoms and cognitive function, as well as any
adverse events and concentrations of the drug at different timepoints.
https://www.nia.nih.gov/alzheimers/clinical-trials/ro7105705-moderate-alzheimers-disease
A Phase 2 trial is enrolling patients with
moderate Alzheimer’s to test an investigational antibody known as
RO7105705 that targets the Tau protein.
The
Genentech-sponsored multicenter, randomized study (
NCT03828747)
intends to assess the efficacy, safety, and pharmacological profile of
RO7105705. The company plans to recruit 260 patients in the U.S. More
information on study locations and contacts can be found
here.
After a screening period, patients will receive RO7105705 or placebo by
intravenous infusion every two weeks for the first three doses and every
four weeks thereafter in a double-blind
treatment
period. Participants can then undergo an optional open-label extension
period which will consist of RO7105705 infusions every four weeks. The
last stage will be a safety follow-up period.
The trial's primary goal is measuring the change in cognitive function
and functional abilities from baseline to week 49.
RO7105705, or MTAU9937A, is being developed by Genentech — owned by
Roche — and
AC Immune.
The treatment candidate is a humanized monoclonal antibody, designed
to stop the cell-to-cell spread of toxic forms of the Tau protein in the
brain. This spread is associated with the onset and progression of
cognitive decline in Alzheimer’s disease.
“Slowing the propagation of Tau